细胞衰老在非酒精性脂肪性肝病发生发展中的作用

张晶; 王炳元; 施军平

doi:10.3969/j.issn.1001-5256.2016.03.008

细胞衰老在非酒精性脂肪性肝病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2016.03.008

1. 中国医科大学附属第一医院老年消化科
2. 杭州师范大学附属医院肝病科

基金项目:

国家自然科学基金项目(81570524)；浙江省自然科学基金项目(LY14H070004;LY15H070004)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2115
- HTML全文浏览量: 15
- PDF下载量: 393
- 被引次数: 0
出版历程
- 收稿日期: 2015-11-05
- 出版日期: 2016-03-20

Role of cell senescence in development and progression of nonalcoholic fatty liver disease

Department of Geriatric Gastroenterology,The First Affiliated Hospital of China Medical University

Research funding:

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)是一种非酒精原因所致的以肝细胞脂肪变性为主要特征的临床病理综合征,肝硬化及肝细胞癌是NAFLD的两个最为重要的肝病结局。细胞衰老是细胞脱离正常周期不可逆地丧失增殖能力后进入的一种相对稳定的状态,是细胞生命活动的一种客观规律。研究表明细胞衰老与NAFLD肝纤维化进程及肝细胞癌变的发生发展密切相关,为NAFLD相关肝硬化及肝细胞癌的防治提供了一个新的思路。
- 脂肪肝 /
- 细胞衰老 /
- 肝硬化 /
- 癌,肝细胞
Abstract: Nonalcoholic fatty liver disease( NAFLD) is a clinicopathological syndrome characterized by fatty degeneration of hepatocytes due to nonalcoholic reasons. Liver cirrhosis and hepatocellular carcinoma are two important outcomes of NAFLD. Cell senescence is a relatively stable state in which cells deviate from the normal cell cycle and experience an irreversible loss of proliferative capacity,which is an objective law in cell life. Research shows that cell senescence is closely associated with the progression of liver fibrosis and the development and progression of hepatocellular carcinoma in NAFLD,and provides a new perspective for the prevention and treatment of liver fibrosis and hepatocellular carcinoma.
- fatty liver /
- cell aging /
- liver cirrhosis /
- carcinoma,hepatocellular

HTML全文

参考文献(34)

[1]TIAN XL,LI Y.Endothelial cellsenescenceand age-related vascular diseases[J].J Genet Genomics,2014,41(9):485-495.

[2]PALMER AK,TCHKONIA T,LEBRASSEUR NK,et al.Cellularsenescencein type 2 diabetes:a therapeutic opportunity[J].Diabetes,2015,64(7):2289-2298.

[3]HOARE M,DAS T,LEXANDER G.Ageing,telomeres,senescence,and liver injury[J].J Hepatol,2010,53(5):950-961.

[4]CAMPISI J.Aging,cellular senescence,and cancer[J].Annu Rev Physiol,2013,75:685-705.

[5]TAKEUCHI S,TAKAHASHI A,MOTOI N,et al.Intrinsic cooperation betweenp16INK4a and p21Waf1/Cip1in the onset of cellular senescence and tumor suppression in vivo[J].Cancer Res,2010,70(22):9381-9390.

[6]CAMPISI J,ROBERT L.Cellsenescence:role inagingand age-related diseases[J].Interdiscip Top Gerontol,2014,39:45-61.

[7]COPPE JP,DESPREZ PY,KRTOLICA A,et al.The senescence-associated secretory phenotype:the dark side of tumor suppression[J].Annu Rev Pathol,2010,5:99-118.

[8]KOSAR M,BARTKOVA J,HUBACKOVA S,et al.Senescenceassociated heterochromatin foci are dispensable for cellular senescence,occur in a cell type-and insult-dependent manner,and follow expression of p16(ink4a)[J].Cell Cycle,2011,10(3):457-468.

[9]KRIZHANOVSKY V,YON M,DICKINS RA,et al.Senescence of activated stellate cells limits liver fibrosis[J].Cell,2008,134(4):657-667.

[10]KLEIN S,KLSEL J,SCHIERWAGEN R,et al.Atorvastatin inhibits proliferation and apoptosis,but inducessenescencein hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats[J].Lab Invest,2012,92(10):1440-1450.

[11]KONG X,FENG D,WANG H,et al.Interleukin-22 induces hepatic stellate cellsenescenceand restrictsliverfibrosis in mice[J].Hepatology,2012,56(3):1150-1159.

[12]NAKAJIMA T,NAKASHIMA T,OKADA Y,et al.Nuclear size measurement is a simple method for the assessment of hepatocellular aging in non-alcoholic fatty liver disease:comparison with telomere-specific quantitative FISH and p21 immunohistochemistry[J].Pathol Int,2010,60(3):175-183.

[13]ARAVINTHAN A,SCARPINI C,TACHTATZIS P,et al.Hepatocyte senescence predicts in non-alcohol-related fatty liver disease[J].J Hepatol,2013,58(3):549-556.

[14]CARULLI L,DEI CAS A,NASCIMBENI F.Synchronous cryptogenic liver cirrhosis and idiopathic pulmonary fibrosis:a clue to telomere involvement[J].Hepatology,2012,56(5):2001-2003.

[15]CHAITEERAKIJ R,ROBERTS LR.Telomerasemutation:ageneticrisk factor for cirrhosis[J].Hepatology,2011,53(5):1430-1432.

[16]CARULLI L,ANZIVINO C.Telomere and telomerase in chronic liver disease and hepatocarcinoma[J].World J Gastroenterol,2014,20(20):6287-6292.

[17]SASAKI M,IKEDA H,YAMAGUCHI J,et al.Bile ductular cells undergoing cellular senescence increase in chronic liver diseases along with fibrous progression[J].Am J Clin Pathol,2010,133(2):212-223.

[18]SYN WK,JUNG Y,OMENETTI A,et al.Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease[J].Gastroenterology,2009,137(4):1478-1488.

[19]CHIBA M,SASAKI M,KITAMURA S,et al.Participation of bile ductular cells in the pathological progression of non-alcoholic fatty liver disease[J].J Clin Pathol,2011,64(7):564-570.

[20]VERMA S,TACHTATZIS P,PENRHYN-LOWE S,et al.Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver[J].Hepatology,2012,56(4):1510-1520.

[21]BAFFY G,BRUNT EM,CALDWELL SH.Hepatocellular carcinoma in non-alcoholic fatty liver disease:an emerging menace[J].J Hepatol,2012,56(6):1384-1391.

[22]ESPOSITO K,CHIODINI P,COLAO A,et al.Metabolic syndrome and risk of cancer:a systematic review and meta-analysis[J].Diabetes Care,2012,35(11):2402-2411.

[23]VANNI E,BUGIANESI E.Obesity and liver cancer[J].Clin Liver Dis,2014,18(1):191-203.

[24]DAVALOS AR,COPPE JP,CAMPISI J,et al.Senescent cells as a source of inflammatory factors for tumor progression[J].Cancer Metastasis Rev,2010,29(2):273-283.

[25]LABERGE RM,AWAD P,CAMPISI J,et al.Epithelial-mesenchymal transition induced by senescent fibroblasts[J].Cancer Microenviron,2012,5(1):39-44.

[26]COULON S,FRANCQUE S,COLLE I,et al.Evaluation of inflammatory and angiogenicfactorsin patients withnon-alcoholic fatty liver disease[J].Cytokine,2012,59(2):442-449.

[27]PARK EJ,LEE JH,YU GY.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression[J].Cell,2010,140(2):197-208.

[28]YEVSA T,KANG TW,ZENDER L.Immune surveillance of pre-cancerous senescent hepatocytes limits hepatocellular carcinoma development[J].Oncoimmunology,2012,1(3):398-399.

[29]FREUND A,ORJALO AV,DESPREZ PY,et al.Inflammatory networks during cellular senescence:causes and consequences[J].Trends Mol Med,2010,16(5):238-246.

[30]YOSHIMOTO S,LOO TM,ATARASHI K,et al.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J].Nature,2013,499(7456):97-101.

[31]CHEN SL,ZHENG MH,SHI KQ,et al.A new strategy for treatment of liver fibrosis letting microRNAs do the job[J].Bio Drugs,2013,27(1):25-34.

[32]Mc CLENDON AK,DEAN JL,ERTEL A,et al.Rb and p53 cooperate to prevent liver tumorigenesis in response to tissue damage[J].Gastroenterology,2011,141(4):1439-1450.

[33]DI J,ZHANG Y,ZHENG J.Reactivation of p53 by inhibiting Mdm2 E3ligase:a novel antitumor approach[J].Curr Cancer Drug Targets,2011,11(8):987-994.

[34]BAKER DJ,WIJSHAKE T,TCHKONIA T,et al.Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders[J].Nature,2011,479(7372):232-236.

施引文献

资源附件(0)

访问统计